Inhaled corticosteroids in COPD.

Inhaled corticosteroids in COPD.

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Brightling, C, Pavord, I
Μορφή:	Journal article
Γλώσσα:	English
Έκδοση:	1999

Παρόμοια τεκμήρια

COPD: an inhaled corticosteroid-resistant, oral corticosteroid-responsive condition.
ανά: Saha, S, κ.ά.
Έκδοση: (2006)

Inhaled corticosteroids in COPD (multiple letters) [1]
ανά: Hart, S, κ.ά.
Έκδοση: (1999)

Inhaled glucocorticoids and COPD exacerbations.
ανά: Brightling, C, κ.ά.
Έκδοση: (2015)

Minimising inhaled corticosteroids for COPD
ανά: Benji Heran, κ.ά.
Έκδοση: (2024-12-01)

Blood eosinophils: a biomarker of COPD exacerbation reduction with inhaled corticosteroids
ανά: Siddiqui, S, κ.ά.
Έκδοση: (2018)

The Use of Inhaled Corticosteroids to Prevent Acute Exacerbations of COPD: A Pro/Con Debate
ανά: Russell, R, κ.ά.
Έκδοση: (2019)

Blood eosinophils: a biomarker of COPD exacerbation reduction with inhaled corticosteroids
ανά: Siddiqui SH, κ.ά.
Έκδοση: (2018-11-01)

Inhaled Corticosteroids and the Lung Microbiome in COPD
ανά: Holly R. Keir, κ.ά.
Έκδοση: (2021-09-01)

How inhaled corticosteroids target inflammation in COPD
ανά: Simon Lea, κ.ά.
Έκδοση: (2023-10-01)

Rational use of inhaled corticosteroids for the treatment of COPD
ανά: Jennifer K. Quint, κ.ά.
Έκδοση: (2023-07-01)

Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma.
ανά: Berry, M, κ.ά.
Έκδοση: (2007)

Comparison of asthma treatment given in addition to inhaled corticosteroids on airway inflammation and responsiveness.
ανά: Green, R, κ.ά.
Έκδοση: (2006)

Reply to: inhaled corticosteroids and adult asthma
ανά: Beasley, R, κ.ά.
Έκδοση: (2019)

Counterpoint: Should an attempt be made to withdraw inhaled corticosteroids in all patients with stable GOLD 3 (30% ≤ FEV1 < 50% predicted) COPD? No.
ανά: Pavord, I
Έκδοση: (2018)

Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids.
ανά: Green, R, κ.ά.
Έκδοση: (2002)

The Role of Dual Bronchodilation and the Conscientious Use of Inhaled Corticosteroid in COPD
ανά: Ricardo G. Figueiredo, κ.ά.
Έκδοση: (2022-08-01)

The dose of inhaled corticosteroids in patients with COPD: when less is better
ανά: Izquierdo JL, κ.ά.
Έκδοση: (2018-10-01)

Quality of life and adherence to inhaled corticosteroids and tiotropium in COPD are related
ανά: Koehorst-ter Huurne K, κ.ά.
Έκδοση: (2016-07-01)

COPD and Osteoporosis: Associated Factors in Patients Treated with Inhaled Corticosteroids
ανά: Ozcakir S, κ.ά.
Έκδοση: (2020-10-01)

Inhaled corticosteroids can reduce osteoporosis in female patients with COPD
ανά: Liu SF, κ.ά.
Έκδοση: (2016-07-01)

Effect of allergic phenotype on treatment response to inhaled bronchodilators with or without inhaled corticosteroids in patients with COPD
ανά: Cheng S, κ.ά.
Έκδοση: (2017-07-01)

Inhaled Corticosteroids in COPD: Trying to Make a Long Story Short
ανά: Tantucci C, κ.ά.
Έκδοση: (2020-04-01)

Prevalence and clinical features of asthma-COPD overlap in patients with COPD not using inhaled corticosteroids
ανά: Kuniaki Hirai, κ.ά.
Έκδοση: (2021-01-01)

Inhaled corticosteroid normalizes some but not all airway vascular remodeling in COPD
ανά: Soltani A, κ.ά.
Έκδοση: (2016-09-01)

Biomarkers predicting response to corticosteroid therapy in asthma.
ανά: Brightling, C, κ.ά.
Έκδοση: (2005)

Asthma progression and mortality: The role of inhaled corticosteroids
ανά: O'Byrne, P, κ.ά.
Έκδοση: (2019)

Inhaled corticosteroid dose is associated with Pseudomonas aeruginosa infection in severe COPD
ανά: Antonio Oliver, κ.ά.
Έκδοση: (2021-01-01)

Inhaled Corticosteroids in COPD: Determinants of Use and Trends in Patient Persistance with Treatment
ανά: Lucie Blais, κ.ά.
Έκδοση: (2004-01-01)

Inhaled Corticosteroid Use Among COPD Patients in Primary Care in Spain
ανά: Miravitlles M, κ.ά.
Έκδοση: (2022-01-01)

Overuse of inhaled corticosteroids in COPD: five questions for withdrawal in daily practice
ανά: Cataldo D, κ.ά.
Έκδοση: (2018-07-01)

Patients with underuse or overuse of inhaled corticosteroids have different perceptions and beliefs regarding COPD and inhaled medication
ανά: Koehorst-ter Huurne K, κ.ά.
Έκδοση: (2018-09-01)

Non-eosinophilic corticosteroid unresponsive asthma.
ανά: Pavord, I, κ.ά.
Έκδοση: (1999)

Scientific rationale for the possible inhaled corticosteroid intraclass difference in the risk of pneumonia in COPD
ανά: Janson C, κ.ά.
Έκδοση: (2017-10-01)

Prednisolone response in patients with COPD.
ανά: Pavord, I, κ.ά.
Έκδοση: (2004)

Sputum IL-5 concentration is associated with a sputum eosinophilia and attenuated by corticosteroid therapy in COPD.
ανά: Bafadhel, M, κ.ά.
Έκδοση: (2009)

Inhaled Corticosteroids
ανά: Peter J. Barnes
Έκδοση: (2010-03-01)

Inhaled Corticosteroid Treatment Regimens and Health Outcomes in a UK COPD Population Study
ανά: Bloom CI, κ.ά.
Έκδοση: (2020-04-01)

Rational use of inhaled corticosteroids for the treatment of COPD: a plain language summary
ανά: Amnon Ariel, κ.ά.
Έκδοση: (2023-11-01)

Use of thiols and implications for the use of inhaled corticosteroids in the presence of oxidative stress in COPD
ανά: Mario Cazzola, κ.ά.
Έκδοση: (2023-07-01)

A descriptive cohort study of withdrawal from inhaled corticosteroids in COPD patients
ανά: Smit Patel, κ.ά.
Έκδοση: (2022-07-01)